Maximus vs CoreAgeRx: price, meds, and telemedicine differences
Quick verdict: Maximus positions itself as a low flat-rate telemedicine option offering compounded semaglutide from U.S. pharmacies at $132.99 per month, while CoreAgeRx emphasizes price stability with semaglutide at $79 per month and tirzepatide at $129 per month; choose based on whether you prioritize a simple low flat rate and U.S. pharmacy sourcing or explicit locked monthly pricing with tirzepatide availability.
Check Maximus pricing and program details
Maximus vs CoreAgeRx at a glance
This Maximus vs CoreAgeRx comparison focuses on five key differences supported by the source: pricing model, medication options, compounded status and regulatory notes, telemedicine and enrollment process, and state or eligibility notes. The introduction gives the early verdict above; the sections below compare each point directly.
Comparison table
| Criteria | Maximus | CoreAgeRx |
|---|---|---|
| Typical monthly price | $132.99 per month (flat rate shown) | Semaglutide $79/month; Tirzepatide $129/month; advertises same price every month |
| Medication options | Compounded semaglutide; limited published detail on tirzepatide | Semaglutide up to 1.0 mg; Tirzepatide any dose up to 7.5 mg advertised |
| Compounded / regulatory | Compounded medications; not FDA-approved and not reviewed by FDA for safety, effectiveness or quality | Notes that medication-specific approval status must be confirmed; branded and compounded products are not interchangeable |
| Telemedicine and visits | Convenient telemedicine access with no clinic visits; prescriptions approved by licensed doctors | 3-minute online visit; no insurance required; treatment subject to clinician determination |
| Pricing stability & fees | Direct-pay model; no insurance billing; no membership fees noted | Promotes flat monthly pricing with no membership fee and no price hikes |
Pricing model: low flat rate versus locked monthly price
Maximus advertises a low flat rate example of $132.99 per month and positions that as one of the lower flat rates on its list. The provider also shows messaging such as starting at $79.99/month in captured landing-page evidence, but the primary cited flat rate is $132.99 per month. CoreAgeRx presents explicit per-medication monthly prices and emphasizes same price every month, with semaglutide at $79 per month and tirzepatide at $129 per month and messaging that prices will not rise month to month. If monthly price stability is a top priority, CoreAgeRx highlights that feature; if a single straightforward low flat example appeals, Maximus highlights its low flat-rate offering.
See CoreAgeRx pricing and enrollment
Medication options and dosing differences
Maximus focuses on compounded semaglutide for once-weekly GLP-1 injections and notes limited published detail on tirzepatide availability. CoreAgeRx specifically advertises both semaglutide up to 1.0 mg and tirzepatide up to 7.5 mg, signaling broader stated medication options on its captured page. Where tirzepatide access matters, CoreAgeRx is explicit about offering it at $129 per month; Maximus does not provide the same level of published detail in the supplied source.
Explore Maximus medication details
Compounded status, regulation, and sourcing
Both sources include regulatory caveats. Maximus clearly states its medication is compounded in U.S.-based pharmacies and includes the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. CoreAgeRx notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Maximus emphasizes trusted U.S. pharmacies as a sourcing point in the supplied evidence.
Telemedicine, enrollment and eligibility
Maximus offers convenient telemedicine access with prescriptions approved by licensed doctors and no in-person clinic visits required. CoreAgeRx advertises a 3-minute online visit and that treatment is available only when a licensed clinician determines it is medically appropriate. CoreAgeRx also advises confirming eligibility, medication, total cost, renewal terms and state availability before enrollment in the captured evidence.
State availability, refunds and other terms
Maximus specifies that its Weight Loss Protocol is available in all 50 states except Mississippi and states that if a patient is not approved for treatment, medication costs will be fully refunded. CoreAgeRx warns that pricing, eligibility, pharmacy, state coverage and renewal terms may change and recommends confirming those details before enrolling. Those differences matter for people who need clear state coverage and refund policies.
Final comparison summary
Maximus vs CoreAgeRx comes down to these tradeoffs: Maximus emphasizes a low flat-rate compounded semaglutide program filled through U.S. pharmacies and telemedicine convenience with a cited $132.99 per month example and specific state availability notes; CoreAgeRx highlights locked monthly pricing per medication, explicit tirzepatide listing at $129 per month, and messaging focused on no price hikes and no membership fees. Both include regulatory qualifiers about compounded or medication-specific approval.
Compare CoreAgeRx eligibility and terms
Choose Maximus if you want a simple direct-pay telemedicine program that emphasizes compounded semaglutide filled through trusted U.S. pharmacies, a low flat-rate example of $132.99 per month, and specific state availability and refund language. Choose CoreAgeRx if you want explicit per-medication monthly pricing with semaglutide at $79 per month and tirzepatide at $129 per month and a service that markets same price every month and no membership fees. This Maximus vs CoreAgeRx summary uses only the supplied evidence and preserves the regulatory and pricing qualifiers provided by each source.